Feature | February 22, 2013| Dave Fornell

FDA Approves Use of Common Abbott Devices to Treat for Coronary CTOs

Additional indications allow its everyday guidewires and balloons to be used in chronic total occlusions (CTOs)

balloon, CTO

Abbott's Mini-Trek balloon dilatation catheter.

guidewire, CTO

Abbott'e HT Pilot guidewire.

February 22, 2013 — Physicians have new tools for treating coronary chronic total occlusions (CTOs) after Abbott received U.S. Food and Drug Administration (FDA) approval this week for guidewires and balloon dilation catheters for treatment of CTOs. Abbott is the only company with FDA approvals of its everyday products for treatment of CTOs.

The FDA approval is for Abbott's HT Progress and HT Pilot guidewires and Mini-Trek balloon dilatation catheter products.

Treatment of CTOs, a 100 percent blockage in the artery, continues to be a controversial topic among cardiac specialists, though estimates indicate that 15 to 20 percent of patients undergoing coronary angiography have a CTO. While some physicians believe they are benign, others believe that CTOs are a slow, silent killer. In addition, treating CTOs with minimally invasive methods is not easy. Up until now, only a handful of specialty CTO products were approved to tackle these lesions.

While the recommended treatment for CTOs varies widely among doctors, many say coronary CTOs offer a potential growth area for patient volume in cath labs. Clinical evidence supports the treatment of CTOs if good procedural outcomes can be obtained. Patients with CTOs can experience significant improvements in quality of life if blood flow is restored to the vessel.

Clearly navigating CTOs can be difficult under 2-D angiography, which only shows a lumengram in the parts of the vessel that are not blocked. The controversy over treating CTOs often involves the guesswork involved when attempting to push wires through the occlusion without piercing the wall of the artery. However, recent advances in 3-D rotational angiography and fusion imaging with these images or computed tomography (CT) or magnetic resonance imaging (MRI) 3-D vessel reconstructions overlaid on live fluoroscopy are expected to greatly aid these types of procedures.

For more information: www.abbottvascular.com

 

 

 

 

Related Content

ACC late breakers
News | ACC| February 09, 2016
February 9, 2016 — The late-breaking clinical trial presentations have been announced for the 2016 American College o
transcatheter repair of a mitral valve paravalvular leak

Transcatheter repair of a surgical mitral replacement paravalvular leak with an Amplatzer Vascular Plug II.

Feature | Heart Valve Repair| February 08, 2016 | Dave Fornell
Off-label use of the St.
Stereotaxis, Philips, collaboration, Niobe ES remote magnetic navigation system, Allura Xper FD10 cardiovascular X-ray

Niobe ES image courtesy of Stereotaxis Inc.

Technology | Cath Lab| February 04, 2016
February 4, 2016 — Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Coopera
medtronic corevalve, tavr
News | February 03, 2016 | Dave Fornell
Medtronic announced Feb. 3 that the U.S.
Medtronic, CE Mark, Resolute Onyx DES, drug-eluting stent, expanded sizes and indications
News | Stents Drug Eluting| February 02, 2016
Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES,...
TOBA-BTK study, six-month results, LINC 2016, Tack Endovascular System
News | Peripheral Arterial Disease (PAD)| January 29, 2016
Intact Vascular Inc. announced that positive six-month results from its Tack Optimized Balloon Angioplasty – Below-the-...
Toshiba, CT-angiography, hybrid OR

Toshiba recently introduced a new line of combined CT and angiography systems, allowing true CT imaging on demand in the interventional lab.

Feature | Angiography| January 27, 2016 | Dave Fornell
All of the major vendors in the United States introduced new systems and technologies in the past few years to reduce...
Technology | Ultrasound Intra-cardiac Echo (ICE)| January 26, 2016
Conavi Medical Inc. (formerly Colibri Technologies Inc.) has received U.S. Food and Drug Administration (FDA) 510(k)...
medical device excise tax, two-year suspension, U.S. market, GlobalData analyst
News | Business| January 25, 2016
The suspension of the medical device excise tax will have positive consequences for the U.S. medical device market over...
Abbott, Absorb, BVS, FDA review, FDA panel

The Abbott Absorb BVS.

News | Cath Lab| January 20, 2016 | Dave Fornell
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel is set to review data and offer...
Overlay Init